A large “big data” study has confirmed the benefits of long-term exposure to disease-modifying therapies (DMTs) in terms of reducing the risk of disability progression in patients with relapsing-remitting MS (RRMS).
News
News
Daily digests of the key conferences in neurology, written by on-site medical journalists.
Published: Sep 12, 2019